The only subcutaneous infliximab formulation available in Australia1
Remsima® SC (infliximab) provides an alternative treatment option for patients with PsA, PSO, RA, CD, UC, and AS.1,2
Remsima® SC is indicated for the treatment of adult patients with moderate to severe plaque psoriasis for whom phototherapy or conventional systemic treatments have been inadequate or are inappropriate1.
The availability of infliximab IV and a subcutaneous formulation of Remsima® provides a treatment approach tailored to the individual needs of your patients.
Remsima® SC can be an expanded treatment option with comparable efficacy and safety to infliximab IV.34
Available in a pre-filled pen and pre-filled syringe with needle guard
Remsima® 120 mg solution for injection in pre-filled pen
Remsima® 120 mg solution for injection in pre-filled syringe with needle guard
AS, ankylosing spondylitis; CD, Crohn’s disease; IV, intravenous; PSA, psoriatic arthritis; PSO, plaque psoriasis; RA, rheumatoid arthritis; SC, subcutaneous; UC, ulcerative colitis
| PBS Information: Authority required for the treatment of adults with severe chronic plaque psoriasis. Refer to the PBS Schedule for full authority information. |
Before prescribing, please review full Product Information available on request from the Celltrion Healthcare Medical Information Service (Phone: 1800 325 228) or www.ebs.tga.gov.au
References: 1. Molloy, J. W., Stengel, J. Z. and Arnold, H. L. (2009) ‘Infliximab: A Review of its Use in the Treatment of Crohn’s Disease’, Clinical Medicine Therapeutics. 2. Rutgeerts, P., Van Assche, G. and Vermeire, S. (2006), Review article: infliximab therapy for inflammatory bowel disease – seven years on. Alimentary Pharmacology & Therapeutics, 23: 451-463. 3. Cha JM et al., Journal Korean Med Sci 2017;32:85–9. 4. Remsima® Product Information. Available at: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/ pdf?OpenAgent&id=CP-2020-PI-02558-1&d=20220706172310101. Accessed on 27.08.2024. 5. Lamb CA et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019;68:s1–s106. 6. Papamichael K et al., Infliximab in inflammatory bowel disease. Ther Adv Chronic Dis. 2019;10: DOI: 2040622319838443. 7. Schreiber, S et al. Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease; J. Gastroenterol. DOI: https://doi.org/10.1053/j.gastro.2021.02.068 Accessed 27.08.2024. 8. Ben-Horin S et al. A novel subcutaneous infliximab (CT-P13): 1-year results including a switch from intravenous infliximab (CT-P13) in patients with active Crohn’s Disease and Ulcerative Colitis. OP24. Presented at ECCO 2020, 12–15 February, Vienna. 9. Reinisch W et al. A Novel Formulation of CT-P13 (Infliximab Biosimilar) for Subcutaneous Administration: 1-Year Result from a Phase I Open-label Randomised Controlled Trial in Patients with Active Crohn’s Disease. DOP62. Presented at ECCO 2019, 6–9 March, Copenhagen. 10. Schreiber S et al. Novel Formulation of CT-P13 (Infliximab Biosimilar) for Subcutaneous Administration: Initial Results from a Phase I Open-Label Randomized Controlled Trial in Patients with Active Crohn’s Disease. Gastroenterology 2018;154(6):S1371. 11. Schreiber S et al. Non-inferiority of Novel Subcutaneous Infliximab (CT-P13) to Intravenous Infliximab (CT-P13) in Patients with Active Crohn’s Disease and Ulcerative Colitis: Week 30 Results from a Multicentre, Randomised Controlled Pivotal Trial. LB02. Presented at UEGW 2019, 19–23 October, Barcelona. 12. EMA Public Assessment Report for Remsima (EMA/376884/2020). Available at: https://www.ema.europa.eu/en/documents/variation-report/remsima-h-c-2576-ii-0082-epar-assessment-report-variation_en.pdf. Accessed on 27.08.2024.